PASSION for PATIENTS

Empowering medically-integrated oncology teams for better patient outcomes.

Join a Patient-Centered Community OF

Cancer Care Professionals

With membership in all 50 states and 7 countries, NCODA is creating a global network of compassionate, patient-centered professionals. By supporting all cancer care professionals in the medically-integrated dispensing of oral cancer therapies, we’re helping to ensure better patient care and achieve more positive outcomes. 

As a member of NCODA, you’re joining a national community focused on the continuous improvement of efficient oral cancer therapy. We’re providing the tools and resources to  support better communications between physicians, oncologists, pharmacists, and administrators.

A female MD with red fingernails holds a mobile device, looking up NCODA resources

Our Mission

We started NCODA with a straightforward mission: to create a space where medically-integrated oncology teams could connect with powerful resources, useful information, and each other to deliver better care for oncology patients around the world. This vision has burgeoned into a global community of compassionate cancer care professionals 

Better Resources for Better Treatment Outcomes.

NCODA brings value to practices through adoption of quality standards, sharing of best practices, and improving financial viability. Plus, our initiatives are specifically designed to give medically-integrated teams every advantage in delivering quality and sustainable care.

Oncolytics Today

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Upcoming Events

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

News

BOSTON–(BUSINESS WIRE)–AVEO Oncology (Nasdaq: AVEO) today announced that FOTIVDA® (tivozanib) is now commercially available in the United States (U.S.) ahead of the previous March 31, 2021 guidance. 

315-655-4640

contact@ncoda.org

LOGIN  |  REGISTER

Oncolytics Today

error: